To investigate the clinical features, treatment and prognosis of critical illness polyneuromyopathy (CIPNM) in patients with severe traumatic brain injury (sTBI) who had positive anti-ganglioside GM1 (anti-GM1) antibody IgG. A case of CIPNM with positive anti-GM1 antibody IgG was retrospectively analysed and followed-up for 30 months. After 1 week of treatment with large dose of short-term glucocorticoid and human immunoglobulin, the muscle strength of both lower extremities was restored to grade 1. Three months later, the muscle strength and muscle tension of the patient's limbs returned to normal except for grade 3 of bilateral dorsal extensor muscle strength. In addition, the patient can walk alone with a waddling gait. After 30 months, there was no recurrence. The application of large dose of short-term glucocorticoid and human immunoglobulin to CIPNM that are positive for anti-GM1 antibodies may be an effective treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1440-1681.13496 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Subacute Upper Motor Neuron Dysfunction Possibly Associated with the Anti-GM1 Autoantibody: A Case Report.
Intern Med
November 2024
Department of Neurology, Graduate School of Medicine, The University of Tokyo, Japan.
Anti-GM1 antibodies are associated with Guillain-Barré syndrome (GBS), primarily peripheral neuropathy. However, there are cases of anti-GM1 IgG antibody-positive GBS with upper motor neuron (UMN) signs. We herein report a case of gastrointestinal infection followed by subacute gait disturbance with predominant signs of UMN on a neurological examination.
View Article and Find Full Text PDFBackground: The incidence of monoclonal gammopathy of undetermined significance (MGUS) in the population of over 50-year-olds is approximately 3% and increases with age. The association between MG and neuropathy has been of interest for several years, but the causal relationship has not yet been clarified.
Methods: For 682 patients who visited the Department of Neurology and requested tests for MG work-up, we retrospectively collected demographic and clinical information, such as age, gender, diagnosis, and neurologic and laboratory test results, from their medical records.
[A study on the effects of Anti-GM1 on the differentiation and cytotoxic activity of NK cells in nude mice].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
September 2024
Department of Urology, Peking University First Hospital; Institute of Urology, Peking University; National Urological Cancer Center, Beijing 100034, China. *Corresponding authors, E-mail:
Article Synopsis
- The study aimed to explore how Anti-ganglioside GM1 antibodies (Anti-GM1) affect the natural killer (NK) cells' ability to kill cancer cells in nude mice by altering their differentiation.
- Researchers used a detailed staining method to identify NK cell characteristics in kidney cancer tissues and immunized mice with GM1 to produce Anti-GM1.
- The results showed that Anti-GM1 significantly reduced NK cell activity, promoted their maturation, and decreased key signaling molecules (IFN-γ and GzmB) involved in their killing function compared to a control group.
Multifocal motor neuropathy in Japan: A nationwide survey on prevalence, clinical profiles, and treatment.
Muscle Nerve
November 2024
Department of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Article Synopsis
- A nationwide survey in Japan assessed multifocal motor neuropathy (MMN), determining its prevalence at 0.40 per 100,000 individuals and identifying 507 estimated patients.
- Most patients were male (2.3:1 ratio), with a median age of onset at 42 and an average diagnosis delay of 25 months.
- Immunoglobulin therapy was administered to 98% of patients, with 91% showing improvement, though slight neurological progression was noted over time.
IgM anti-GM2 antibodies in patients with multifocal motor neuropathy target Schwann cells and are associated with early onset.
J Neuroinflammation
April 2024
Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht, The Netherlands.
Background: Multifocal motor neuropathy (MMN) is a rare, chronic immune-mediated polyneuropathy characterized by asymmetric distal limb weakness. An important feature of MMN is the presence of IgM antibodies against gangliosides, in particular GM1 and less often GM2. Antibodies against GM1 bind to motor neurons (MNs) and cause damage through complement activation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!